Servier Completes Acquisition of Day One Biopharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Source: PRnewswire
- Acquisition Finalized: Servier has successfully acquired Day One Biopharmaceuticals at $21.50 per share, enhancing its leadership in low-grade glioma and solidifying its oncology market position.
- Strategic Advancement: This acquisition marks a significant step in Servier's ambition for 2030, particularly in treating pediatric low-grade gliomas, aiming to enhance support for patients with rare cancers.
- Portfolio Expansion: Day One's portfolio includes the FDA-approved OJEMDATM (tovorafenib), a treatment for the most common brain tumor in children, and its pipeline features several innovative drugs across various clinical stages.
- Integration of Scientific Capabilities: The scientific and clinical expertise of Day One will be integrated with Servier's resources to drive long-term innovation, ensuring effective treatment solutions for patients with rare cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
